Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as Phase I hemophilia candidate ALN-AT3. ALN-CC5, a preclinical paroxysmal nocturnal hemoglobinuria (PNH) candidate, and ALN-AS1, a preclinical asymptomatic acute intermittent porphyria (AIP) candidate, are also included in the program. Alnylam plans to commercialize genetic medicine products in the U.S. and EU. The Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) will commercialize the products elsewhere.

Cardio-metabolic disease programs include Phase I candidate ALN-PCSsc for hypercholesterolemia; preclinical candidates ALN-AC3 and ALN-ANG to treat hypertriglyceridemia; and preclinical candidate ALN-AGT to treat hypertensive disorders of pregnancy. Alnylam is also developing undisclosed preclinical programs to treat non-alcoholic steatohepatitis (NASH) and Type II diabetes. ...